Year-over-year net earnings per share growth for the last 12 months: Universe Pharma (UPC)

Brandmark of Universe Pharmaceuticals (UPC)

Universe Pharmaceuticals is implementing AI control and automation in raw material processing. However, government price regulations in China and the battle for the generics market are reducing free cash flow. The quarterly change in earnings per share confirms volatility, where 71.50 represents the latest level. Meanwhile, a focus on elderly longevity positions the company as a leader in the traditional medicine segment.

Universe Pharmaceuticals INC (UPC) - Earnings per share growth in annualized terms for the last twelve months from 07/04/2022 to 11/16/2026

Summary analytical data breakdowns for Universe Pharmaceuticals (UPC)

- share price and expert price forecast:
- company stock exchange capitalization indicators:
Comprehensive company analysis:Universe Pharmacy, UPC
Manufactured product of Universe Pharma

The indicator calculates net profit per share dynamics, stripping accounting data of one-off noise to identify the real value trend. Growth in this metric confirms the effectiveness of Universe Pharmaceuticals (UPC) investments in R&D and AI-driven production control; however, the upward trend in quarterly EPS growth signals to investors the need to balance yield potential against the risk of overpaying for the asset.